{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:34Z","timestamp":1792460314205,"version":"4.5.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/fpc.0b013e32835ea0b2","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T09:46:32Z","timestamp":1360748792000},"page":"236-241","source":"Crossref","is-referenced-by-count":381,"title":["Valproic acid pathway"],"prefix":"10.1097","volume":"23","author":[{"given":"Yogita","family":"Ghodke-Puranik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline F.","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder K.","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Steven","family":"Leeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ B.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri E.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Pt 5","key":"R2-8-20210213","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1042\/BST0371126","article-title":"Structure-function studies for the panacea, valproic acid.","volume":"37","author":"Terbach","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"R3-8-20210213","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","article-title":"Valproate population pharmacokinetics in children.","volume":"24","author":"Serrano","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"R4-8-20210213","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","article-title":"Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.","volume":"20","author":"Blanco-Serrano","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"R5-8-20210213","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.","volume":"55","author":"Aires","year":"2011","journal-title":"J Hepatol"},{"key":"R6-8-20210213","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1749-6632.2009.05113.x","article-title":"Epilepsy in the elderly.","volume":"1184","author":"Leppik","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R7-8-20210213","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0304-4165(90)90079-C","article-title":"The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase.","volume":"1034","author":"Ito","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"R8-8-20210213","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10.","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R9-8-20210213","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.","volume":"112","author":"Tan","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"R10-8-20210213","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-8-20210213","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","article-title":"Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.","volume":"83","author":"Chung","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R12-8-20210213","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases.","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"R13-8-20210213","first-page":"525","article-title":"Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans.","volume":"19","author":"Kassahun","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"R14-8-20210213","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0009-2797(94)90014-0","article-title":"Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes.","volume":"90","author":"Kassahun","year":"1994","journal-title":"Chem Biol Interact"},{"key":"R15-8-20210213","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/tx00047a006","article-title":"Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.","volume":"8","author":"Tang","year":"1995","journal-title":"Chem Res Toxicol"},{"key":"R16-8-20210213","first-page":"1210","article-title":"Effect of alpha-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats.","volume":"29","author":"Grillo","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R17-8-20210213","first-page":"1098","article-title":"In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.","volume":"21","author":"Kassahun","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"R18-8-20210213","first-page":"81","article-title":"Studies on the biotransformation in the perfused rat liver of 2-N-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.","volume":"13","author":"Rettenmeier","year":"1985","journal-title":"Drug Metab Dispos"},{"key":"R19-8-20210213","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/tx00004a001","article-title":"Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-N-propyl-4-pentenoic acid.","volume":"1","author":"Baillie","year":"1988","journal-title":"Chem Res Toxicol"},{"key":"R20-8-20210213","first-page":"823","article-title":"Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals.","volume":"28","author":"Gopaul","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R21-8-20210213","first-page":"698","article-title":"Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.","volume":"283","author":"Sadeque","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R22-8-20210213","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C911 genotype.","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicol Sci"},{"key":"R23-8-20210213","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.","volume":"3","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"R24-8-20210213","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future.","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev"},{"key":"R25-8-20210213","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00228395","article-title":"Valproate and sodium currents in cultured hippocampal neurons.","volume":"93","author":"Van den Berg","year":"1993","journal-title":"Exp Brain Res"},{"key":"R26-8-20210213","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"R27-8-20210213","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J"},{"key":"R28-8-20210213","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"key":"R29-8-20210213","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization.","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R30-8-20210213","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/jpet.300.2.361","article-title":"The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.","volume":"300","author":"McCarver","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R31-8-20210213","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/15376516.2010.497977","article-title":"Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.","volume":"20","author":"Amini-Shirazi","year":"2010","journal-title":"Toxicol Mech Methods"},{"key":"R32-8-20210213","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajpath.2010.10.023","article-title":"DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma.","volume":"178","author":"Liu","year":"2011","journal-title":"Am J Pathol"},{"key":"R33-8-20210213","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1442-200X.2010.03157.x","article-title":"Effect of CPS14217CA genotype on valproic-acid-induced hyperammonemia.","volume":"52","author":"Yagi","year":"2010","journal-title":"Pediatr Int"},{"key":"R34-8-20210213","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.HYP.0000112424.06921.52","article-title":"Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function.","volume":"43","author":"Summar","year":"2004","journal-title":"Hypertension"},{"key":"R36-8-20210213","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng1235","article-title":"Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder.","volume":"35","author":"Kakiuchi","year":"2003","journal-title":"Nat Genet"},{"key":"R37-8-20210213","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.psychres.2008.05.010","article-title":"Preliminary evidence on the association between XBP1-116CG polymorphism and response to prophylactic treatment with valproate in bipolar disorders.","volume":"168","author":"Kim","year":"2009","journal-title":"Psychiatry Res"},{"key":"R38-8-20210213","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/sj.mp.4001152","article-title":"Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia.","volume":"7","author":"Miyatake","year":"2002","journal-title":"Mol Psychiatry"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0b013e32835ea0b2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:27:30Z","timestamp":1620952050000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201304000-00008"}},"subtitle":["pharmacokinetics and pharmacodynamics"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32835ea0b2","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}